Anatomical Therapeutic Chemical • L04AF02 • baricitinib

L Antineoplastic and immunomodulating agents

L01 Antineoplastic agents

L02 Endocrine therapy

L03 Immunostimulants

L04 Immunosuppressants

L04A Immunosuppressants

L04AA Selective immunosuppressants

L04AB Tumor necrosis factor alpha (tnf-alpha) inhibitors

L04AC Interleukin inhibitors

L04AD Calcineurin inhibitors

L04AE Sphingosine-1-phosphate (S1P) receptor modulators

L04AF Janus-associated kinase (JAK) inhibitors

L04AF01 tofacitinib Indicated for: autoimmune inflammatory diseases

L04AF02 baricitinib Indicated for: rheumatoid arthritis; atopic dermatitis; COVID-19

L04AF03 upadacitinib Indicated for: inflammatory bowel disease

L04AF04 filgotinib Indicated for: inflammatory bowel disease

L04AF07 deucravacitinib Indicated for: autoimmune inflammatory diseases

L04AF08 ritlecitinib Indicated for: severe alopecia areata

L04AG Monoclonal antibodies

L04AH Mammalian target of rapamycin (mTOR) kinase inhibitors

L04AJ Complement inhibitors

L04AK Dihydroorotate dehydrogenase (DHODH) inhibitors

L04AL Neonatal fragment crystallizable receptor (fcrn) inhibitors

L04AX Other immunosuppressants